Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sotyktu
Biotech
Alumis plans IPO to fund TYK2 inhibitor through phase 3 trials
Not content with bringing in one of the largest private biotech fundraises of 2024, Alumis is the latest company to set its sights on the Nasdaq.
James Waldron
Jun 10, 2024 8:35am
How Takeda beat the rest of the industry to snag Nimbus' TYK2
Jan 11, 2024 10:30am
Nimbus tacks on $210M as investors swat away IRA concerns
Sep 6, 2023 7:00am
Takeda's $4B drug clears psoriasis in one-third of patients
Mar 20, 2023 8:15am
Takeda bets $4B upfront on Nimbus' phase 3-ready psoriasis drug
Dec 13, 2022 9:30am
Nimbus posts psoriasis data on rival to Bristol Myers' Sotyktu
Nov 30, 2022 6:00am
